Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma

The European T-Cell Lymphoma Study Group, T-Cell Project: Prospective Collection of Data in Patients with Peripheral T-Cell Lymphoma and the AIRC 5xMille Consortium Genetics-Driven Targeted Management of Lymphoid Malignancies

Research output: Contribution to journalArticle

164 Citations (Scopus)

Abstract

A systematic characterization of the genetic alterations driving ALCLs has not been performed. By integrating massive sequencing strategies, we provide a comprehensive characterization of driver genetic alterations (somatic point mutations, copy number alterations, and gene fusions) in ALK- ALCLs. We identified activating mutations of JAK1 and/or STAT3 genes in ~20% of 155 ALK- ALCLs and demonstrated that 38% of systemic ALK- ALCLs displayed double lesions. Recurrent chimeras combining a transcription factor (NFkB2 or NCOR2) with a tyrosine kinase (ROS1 or TYK2) were also discovered in WT JAK1/STAT3 ALK- ALCL. All these aberrations lead to the constitutive activation of the JAK/STAT3 pathway, which was proved oncogenic. Consistently, JAK/STAT3 pathway inhibition impaired cell growth invitro and invivo.

Original languageEnglish (US)
Pages (from-to)516-532
Number of pages17
JournalCancer Cell
Volume27
Issue number4
DOIs
StatePublished - Apr 13 2015

Fingerprint

Anaplastic Large-Cell Lymphoma
Gene Fusion
Point Mutation
Protein-Tyrosine Kinases
Transcription Factors
Phosphotransferases
Mutation
Growth
Genes

ASJC Scopus subject areas

  • Oncology
  • Cell Biology
  • Cancer Research

Cite this

The European T-Cell Lymphoma Study Group, T-Cell Project: Prospective Collection of Data in Patients with Peripheral T-Cell Lymphoma and the AIRC 5xMille Consortium Genetics-Driven Targeted Management of Lymphoid Malignancies (2015). Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell, 27(4), 516-532. https://doi.org/10.1016/j.ccell.2015.03.006

Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. / The European T-Cell Lymphoma Study Group, T-Cell Project: Prospective Collection of Data in Patients with Peripheral T-Cell Lymphoma and the AIRC 5xMille Consortium Genetics-Driven Targeted Management of Lymphoid Malignancies.

In: Cancer Cell, Vol. 27, No. 4, 13.04.2015, p. 516-532.

Research output: Contribution to journalArticle

The European T-Cell Lymphoma Study Group, T-Cell Project: Prospective Collection of Data in Patients with Peripheral T-Cell Lymphoma and the AIRC 5xMille Consortium Genetics-Driven Targeted Management of Lymphoid Malignancies 2015, 'Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma', Cancer Cell, vol. 27, no. 4, pp. 516-532. https://doi.org/10.1016/j.ccell.2015.03.006
The European T-Cell Lymphoma Study Group, T-Cell Project: Prospective Collection of Data in Patients with Peripheral T-Cell Lymphoma and the AIRC 5xMille Consortium Genetics-Driven Targeted Management of Lymphoid Malignancies. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell. 2015 Apr 13;27(4):516-532. https://doi.org/10.1016/j.ccell.2015.03.006
The European T-Cell Lymphoma Study Group, T-Cell Project: Prospective Collection of Data in Patients with Peripheral T-Cell Lymphoma and the AIRC 5xMille Consortium Genetics-Driven Targeted Management of Lymphoid Malignancies. / Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. In: Cancer Cell. 2015 ; Vol. 27, No. 4. pp. 516-532.
@article{1dcaaf6e7ad54bde89612ca1f87713e6,
title = "Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma",
abstract = "A systematic characterization of the genetic alterations driving ALCLs has not been performed. By integrating massive sequencing strategies, we provide a comprehensive characterization of driver genetic alterations (somatic point mutations, copy number alterations, and gene fusions) in ALK- ALCLs. We identified activating mutations of JAK1 and/or STAT3 genes in ~20{\%} of 155 ALK- ALCLs and demonstrated that 38{\%} of systemic ALK- ALCLs displayed double lesions. Recurrent chimeras combining a transcription factor (NFkB2 or NCOR2) with a tyrosine kinase (ROS1 or TYK2) were also discovered in WT JAK1/STAT3 ALK- ALCL. All these aberrations lead to the constitutive activation of the JAK/STAT3 pathway, which was proved oncogenic. Consistently, JAK/STAT3 pathway inhibition impaired cell growth invitro and invivo.",
author = "{The European T-Cell Lymphoma Study Group, T-Cell Project: Prospective Collection of Data in Patients with Peripheral T-Cell Lymphoma and the AIRC 5xMille Consortium Genetics-Driven Targeted Management of Lymphoid Malignancies} and Ramona Crescenzo and Francesco Abate and Elena Lasorsa and Fabrizio Tabbo' and Marcello Gaudiano and Nicoletta Chiesa and {Di Giacomo}, Filomena and Elisa Spaccarotella and Luigi Barbarossa and Elisabetta Ercole and Maria Todaro and Michela Boi and Andrea Acquaviva and Elisa Ficarra and Domenico Novero and Andrea Rinaldi and Thomas Tousseyn and Andreas Rosenwald and Lukas Kenner and Lorenzo Cerroni and Alexander Tzankov and Maurilio Ponzoni and Marco Paulli and Dennis Weisenburger and Chan, {Wing C.} and Javeed Iqbal and Piris, {Miguel A.} and Alberto Zamo' and Carmela Ciardullo and Davide Rossi and Gianluca Gaidano and Stefano Pileri and Enrico Tiacci and Brunangelo Falini and Shultz, {Leonard D.} and Laurence Mevellec and Vialard, {Jorge E.} and Roberto Piva and Francesco Bertoni and Raul Rabadan and Giorgio Inghirami",
year = "2015",
month = "4",
day = "13",
doi = "10.1016/j.ccell.2015.03.006",
language = "English (US)",
volume = "27",
pages = "516--532",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "4",

}

TY - JOUR

T1 - Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma

AU - The European T-Cell Lymphoma Study Group, T-Cell Project: Prospective Collection of Data in Patients with Peripheral T-Cell Lymphoma and the AIRC 5xMille Consortium Genetics-Driven Targeted Management of Lymphoid Malignancies

AU - Crescenzo, Ramona

AU - Abate, Francesco

AU - Lasorsa, Elena

AU - Tabbo', Fabrizio

AU - Gaudiano, Marcello

AU - Chiesa, Nicoletta

AU - Di Giacomo, Filomena

AU - Spaccarotella, Elisa

AU - Barbarossa, Luigi

AU - Ercole, Elisabetta

AU - Todaro, Maria

AU - Boi, Michela

AU - Acquaviva, Andrea

AU - Ficarra, Elisa

AU - Novero, Domenico

AU - Rinaldi, Andrea

AU - Tousseyn, Thomas

AU - Rosenwald, Andreas

AU - Kenner, Lukas

AU - Cerroni, Lorenzo

AU - Tzankov, Alexander

AU - Ponzoni, Maurilio

AU - Paulli, Marco

AU - Weisenburger, Dennis

AU - Chan, Wing C.

AU - Iqbal, Javeed

AU - Piris, Miguel A.

AU - Zamo', Alberto

AU - Ciardullo, Carmela

AU - Rossi, Davide

AU - Gaidano, Gianluca

AU - Pileri, Stefano

AU - Tiacci, Enrico

AU - Falini, Brunangelo

AU - Shultz, Leonard D.

AU - Mevellec, Laurence

AU - Vialard, Jorge E.

AU - Piva, Roberto

AU - Bertoni, Francesco

AU - Rabadan, Raul

AU - Inghirami, Giorgio

PY - 2015/4/13

Y1 - 2015/4/13

N2 - A systematic characterization of the genetic alterations driving ALCLs has not been performed. By integrating massive sequencing strategies, we provide a comprehensive characterization of driver genetic alterations (somatic point mutations, copy number alterations, and gene fusions) in ALK- ALCLs. We identified activating mutations of JAK1 and/or STAT3 genes in ~20% of 155 ALK- ALCLs and demonstrated that 38% of systemic ALK- ALCLs displayed double lesions. Recurrent chimeras combining a transcription factor (NFkB2 or NCOR2) with a tyrosine kinase (ROS1 or TYK2) were also discovered in WT JAK1/STAT3 ALK- ALCL. All these aberrations lead to the constitutive activation of the JAK/STAT3 pathway, which was proved oncogenic. Consistently, JAK/STAT3 pathway inhibition impaired cell growth invitro and invivo.

AB - A systematic characterization of the genetic alterations driving ALCLs has not been performed. By integrating massive sequencing strategies, we provide a comprehensive characterization of driver genetic alterations (somatic point mutations, copy number alterations, and gene fusions) in ALK- ALCLs. We identified activating mutations of JAK1 and/or STAT3 genes in ~20% of 155 ALK- ALCLs and demonstrated that 38% of systemic ALK- ALCLs displayed double lesions. Recurrent chimeras combining a transcription factor (NFkB2 or NCOR2) with a tyrosine kinase (ROS1 or TYK2) were also discovered in WT JAK1/STAT3 ALK- ALCL. All these aberrations lead to the constitutive activation of the JAK/STAT3 pathway, which was proved oncogenic. Consistently, JAK/STAT3 pathway inhibition impaired cell growth invitro and invivo.

UR - http://www.scopus.com/inward/record.url?scp=84928015700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928015700&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2015.03.006

DO - 10.1016/j.ccell.2015.03.006

M3 - Article

C2 - 25873174

AN - SCOPUS:84928015700

VL - 27

SP - 516

EP - 532

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 4

ER -